Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Thomas Jefferson University
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Manchester
University of California, Irvine
M.D. Anderson Cancer Center
City of Hope Medical Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Southern California
University of Michigan Rogel Cancer Center
M.D. Anderson Cancer Center
China-Japan Friendship Hospital
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Ciusss de L'Est de l'Île de Montréal
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University Hospital, Basel, Switzerland
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
Stanford University
Haukeland University Hospital
M.D. Anderson Cancer Center
Thomas Jefferson University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Columbia University
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
Indiana University
University Hospital, Basel, Switzerland
M.D. Anderson Cancer Center
Indiana University
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
University of Nebraska
M.D. Anderson Cancer Center
University of Washington